This content is machine translated Online training Swiss Oncology in Motion Ovarian Cancer Module Around 600 women are affected by ovarian cancer in Switzerland every year. Due to the non-specific symptoms, the disease is often only diagnosed at an advanced stage and most patients…
View Post 2 min This content is machine translated Multiple sclerosis Glatiramer acetate now also approved for use in the breastfeeding period Glatiramer acetate 20 mg/ml and 40 mg/ml, indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in Europe, has updated its SmPC. The product is now approved for…
View Post 8 min This content is machine translated Vulvar and vaginal carcinoma Update: precancerous lesions, classification and therapy While vaginal cancer is a rarity, cases of vulvar cancer have increased significantly worldwide over the past 20 years. It is the female carcinoma whose incidence is increasing most rapidly.…
View Post 2 min This content is machine translated Breast Cancer Regulatory extension for anti-PD-1 therapy with pembrolizumab Swissmedic has granted a further marketing authorization for anti-PD-1 therapy with pembrolizumab. This can now be approved in combination with chemotherapy in Switzerland for the treatment of patients with locally…
View Post 9 min This content is machine translated Locally advanced/metastatic breast carcinoma 44th San Antonio Breast Cancer Symposium: Best Of From December 7-10, 2021, the 44th San Antonio Breast Cancer Symposium took place in a physical-virtual hybrid event. In a series of exciting lectures, the latest clinical and preclinical findings…
View Post 3 min This content is machine translated Rheumatism Safe through pregnancy thanks to medication management Medication can also protect women with rheumatoid arthritis from a disease flare-up during pregnancy. This is shown by the results of a study from the Netherlands. However, some women may…
View Post 3 min This content is machine translated HRD-positive advanced ovarian cancer. PARP inhibitor recommended for first-line maintenance therapy Poly-ADP-ribose polymerase (PARP) inhibitors have added valuable options to the therapeutic landscape in advanced ovarian cancer and have already found their way into ASCO and NCCN guidelines [1–3]. With the…
View Post 9 min This content is machine translated Ovarian tumors Therapy Update For both germ cell and epithelial ovarian tumors, the first line of therapy is surgery and chemotherapy. However, there has been a lot of progress over the last few years,…
View Post 4 min This content is machine translated Axial spondyloarthritis (axSpA) and osteoporosis Challenges and successes in the therapy of female patients Lack of awareness of gender differences may lead to suboptimal treatment [1]. Prof. Andrea Rubbert-Roth, Dr. Diana Dan and PD Dr. Brigitte Uebelhart spoke at this year’s congress of the…
View Post 6 min This content is machine translated Osteoporosis Clarify risk patients densitometrically and treat them in an individualized manner The risk of suffering an osteoporosis-related fracture is significantly increased with certain predisposing factors. This should be increasingly taken into account because, according to the Swiss Association against Osteoporosis (SVGO),…
View Post 8 min This content is machine translated Advanced breast carcinoma What’s new? With antibody-drug conjugates, checkpoint and CDK4/6 inhibitors, three drug classes were in the spotlight at this year’s European Society for Medical Oncology (ESMO) congress in advanced breast cancer. This is…
